Answers are grounded in this paper and cite their sources.
Nanozyme catalytic therapy triggered by tumor-specific endogenous stimuli is an emerging tumor therapy that attracts wide attention. However, the current therapeutic efficacy of nanozyme catalytic therapy is severely limited by the catalytic efficiency of nanozymes and the concentration of endogenous reaction substrates. Herein, a novel and efficient IrN₅ single-atom (IrN₅ SA) nanozyme is developed with multiple enzyme-like catalytic activities. Due to the synergistic effect of central Ir single-atom and axial N coordination, IrN₅ SA exhibits better enzymatic catalytic performance than IrN₄ SA. At tumor sites, IrN₅ SA can generate a large amount of reactive oxygen species (ROS) through oxidase (OXD)-like and peroxidase (POD)-like catalytic activities. Moreover, IrN₅ SA can also generate O₂ and hydrogen peroxide (H₂ O₂ ) through catalase (CAT)-like and nicotinamide adenine dinucleotide (NADH) oxidase (NOX)-like catalytic activities, realizing the efficient nanozyme catalytic therapy in a substrate-cycle manner. Additionally, IrN₅ SA can effectively break the intracellular NADH/NAD⁺ cycle balance by mimicking NOX, and then cooperate with fatty acid synthase cerulenin (Cer) to interfere with the energy metabolism homeostasis of tumor cells. Consequently, the designed IrN₅ SA/Cer nanoagent can disrupt redox and metabolic homeostasis in the tumor region through an enzyme-mimicking cascade reaction, effectively overcoming the shortcomings of current nanozyme catalytic therapy.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: